<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11860577</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.143</article-id><article-id pub-id-type="other">O0007</article-id><article-id pub-id-type="pii">S0924933824001433</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>Oral Communication</subject></subj-group></article-categories><title-group><article-title>Exploring predictors of Treatment Attendance in Patients with PTSD and Comorbid Personality Disorders: Secondary Analysis of a Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van den End</surname><given-names>A.</given-names></name><xref rid="aff0012" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0013" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Snoek</surname><given-names>A.</given-names></name><xref rid="aff0012" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0014" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor0004" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Aarts</surname><given-names>I.</given-names></name><xref rid="aff0012" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0015" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lommerse</surname><given-names>N.</given-names></name><xref rid="aff0016" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dekker</surname><given-names>J.</given-names></name><xref rid="aff0016" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff0017" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Beekman</surname><given-names>A. T. F.</given-names></name><xref rid="aff0013" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Thomaes</surname><given-names>K.</given-names></name><xref rid="aff0012" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0013" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff0015" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff0018" ref-type="aff">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="aff0012"><sup>1</sup>Sinai Centre, <city>Amstelveen</city></aff><aff id="aff0013"><sup>2</sup>Psychiatry, Vrije Universiteit Medical Centre, <city>Amsterdam</city></aff><aff id="aff0014"><sup>3</sup>Psychiatry, Vrije Universiteit Medical Centre, <city>Amstelveen</city></aff><aff id="aff0015"><sup>4</sup>Anatomy and Neurosciences, Vrije Universiteit Medical Centre</aff><aff id="aff0016"><sup>5</sup>Arkin</aff><aff id="aff0017"><sup>6</sup>Clinical Psychology, Vrije Universiteit, <city>Amsterdam</city></aff><aff id="aff0018"><sup>7</sup>Arkin, <city>Amstelveen</city>, <country>Netherlands</country></aff><author-notes><corresp id="cor0004"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="118">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S43</fpage><lpage>S43</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824001433a.pdf"/><abstract><sec id="sec0019"><title>Introduction</title><p>Posttraumatic stress disorder (PTSD) and personality disorders (PD) often co-occur&#x000a0;and treatment dropout remains a challenging problem for both disorders. The literature on predictors of treatment dropout is highly mixed and few reliable predictors have been identified for both PTSD and PD treatments separately, let alone for concurrent PTSD and PD treatment.</p></sec><sec id="sec0020"><title>Objectives</title><p>The aim of the present study was to identify predictors of treatment attendance among a wide range of variables in patients with PTSD and comorbid PD who received trauma-focused treatment with and without concurrent PD treatment.</p></sec><sec id="sec0021"><title>Methods</title><p>Data were used from the prediction and outcome study in comorbid PTSD and personality disorders (PROSPER), a study consisting of two randomized clinical trials (RCT) testing the effectiveness of trauma-focused treatment (eye movement desensitization and reprocessing or imagery rescripting) with versus without concurrent PD treatment (dialectical behavior therapy or group schema therapy). 256 patients with PTSD and comorbid personality disorder participated in the study. The potential predictors included demographic (e.g. work status), patient severity (e.g. PTSD severity), patient-therapist (e.g. working alliance) and therapist (e.g. therapist experience) variables. The ordinal outcome variable was treatment attendance (0, 1-7, 8-11, 12+ trauma-focused treatment sessions). Relevant predictors were identified by a series of ordinal regression analyses (threshold for inclusion p &#x0003c; .10). Relevant predictors were then entered together in a final ordinal regression model. Multiple imputation was used to handle missing data.</p></sec><sec id="sec0022"><title>Results</title><p>The final model included ten predictor variables and provided a good fit for the data (pooled R<sup>2</sup><sub>Nagelkerke</sub> = .29). Higher education level (OR = 1.22, p = .009), self-rated PTSD severity (OR = 1.04, p = .036) and working alliance (OR = 1.72, p = .047) were associated with a larger number of attended sessions. Higher levels of inadequate social support from a friend (OR = 0.90, p = .042) and being randomized in the concurrent treatment condition (OR = 0.52, p = .022) were&#x000a0;associated with a smaller number of attended sessions.</p></sec><sec id="sec0023"><title>Conclusions</title><p>In terms of treatment attendance rates, the results suggest that trauma-focused treatment is preferred over concurrent trauma-focused and personality disorder treatment for patients presenting with PTSD and PD. Clinicians should further be aware of the risk of lower treatment attendance for patients with a lower educational background and those reporting inadequate social support. Enhancing working alliance may protect against early treatment termination. Finally, patients with higher levels of PTSD severity at baseline may need a larger number of treatment sessions.</p></sec><sec id="sec0024"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>